That clinical trials for a cholesterol-lowering drug exceed expectations will boost the developer's stock, says CNBC's Jim Cramer.» Read More
*India welcomes U.S. trade decision. NEW DELHI, May 1- India said on Thursday it would hold trade talks on intellectual property rights with the United States after its general election, buying time to address friction over drug patents until a new government is formed.
Merck is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter.
NEW YORK/ LONDON, April 30- Merck& Co Inc is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter, as the U.S. drugmaker continues to streamline businesses to focus on high-growth areas.
Headlines after the bell Wednesday: Allergan, MetLife, Yelp
*Alstom jumps; among most shorted stocks on Paris bourse. Alstom jumped 9.3 percent after saying it would review a binding offer from General Electric for its energy business by the end of May and left the door open for a competing bid from Germany's Siemens.
*Alstom jumps; among most shorted stocks on Paris bourse. Alstom jumped 9.8 percent after saying it would review a binding offer from General Electric for its energy business by the end of May and left the door open for a competing bid from Germany's Siemens.
Some of the names on the move ahead of the open.
*Sanofi looking to sell mature products with $3.7 bln sales. *Sanofi shares gain 1.5 percent. Shares in Sanofi rose 1.5 percent in early trade on Wednesday following the news.
LONDON/ NEW YORK, April 29- Sanofi SA is looking to sell a portfolio of mature drugs that could fetch between $7 billion and $8 billion, according to people familiar with the matter, yet another example of drugmakers trying to shed non-core assets and focus on high-growth areas.
April 29- Amicus Therapeutics Inc said its experimental drug significantly reduced the abnormal accumulation of fat in body cells related to a rare genetic disorder that could lead to heart attack, stroke and kidney failure.
LONDON, April 29- U.S. drugmaker Pfizer will need to raise its bid for AstraZeneca to around $105- 110 billion and increase the proportion of cash in the offer to win its British rival, investors believe.
U.S. stock index futures pointed to a higher open, ahead of first quarter earnings from companies including Twitter and eBay.
*Q1 sales fall 2.7 pct to 7.84 bln eur, EPS 1.17 eur. PARIS, April 29- French drugmaker Sanofi reported lower-than-expected first-quarter earnings on Tuesday and said it would not let an M&A buzz in the sector distract it from its strategy of targeted, reasonably priced acquisitions.
PARIS, April 29- French drugmaker Sanofi reported lower-than-expected first-quarter earnings on Tuesday, weighed down by a delay in supply of paediatric vaccines in emerging markets and generic competition in animal health.
April 25- JPMorgan Chase& Co's global chairman of investment banking and veteran deal maker James Elliott will retire in June, according to an internal memo seen by Reuters.
April 25- Cytokinetics Inc said its experimental treatment for Lou Gehrig's disease- a progressive neurodegenerative disorder- failed the main goal in a mid-stage trial, sending its shares down about 60 percent before the bell.
LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.
LONDON, April 23- The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.
*FTSEurofirst 300 up 0.9 pct, Euro STOXX 50 up 0.7 pct. *AstraZeneca jumps 7.4 pct on M&A talk. The euro zone's blue-chip Euro STOXX 50 index added 0.7 percent, to 3,175.96 points.
This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.